SCHEMBL6027124

SCHEMBL6027124

Cc1cccc(C(=O)NCCN(C)C)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.59
GRM5 P41594 1/20 0.53
ALOX15 P16050 1/20 0.49
HTT P42858 2/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 1/20 0.48
RAD52 P43351 4/20 0.47
HTR2C P28335 1/20 0.47
AOX1 Q06278 1/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
SMARCA2 P51531 1/20 0.45
OPRM1 P35372 1/20 0.45
OPRK1 P41145 1/20 0.45
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
MAPT P10636 1/20 0.45
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12247948 0.91 LMNA (0.57) ALOX15HTTPOLBSMN1; SMN2LMNA
SCHEMBL6451392 0.84 P2RX7 (0.67) P2RX7GRM5SMN1; SMN2LMNAALDH1A1
SCHEMBL30074544 0.84 RAD52 (0.52) ALOX15HTTPOLBSMN1; SMN2LMNA
SCHEMBL6931 0.84 ALDH1A1 (0.57) GRM5ALOX15POLBLMNARAD52
SCHEMBL10707099 0.83 P2RX7 (0.65) P2RX7GRM5POLBSMN1; SMN2LMNA
SCHEMBL30695493 0.81 P2RX7 (0.63) P2RX7GRM5POLBSMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL10709499 0.80 P2RX7 (0.66) P2RX7GRM5SMN1; SMN2LMNAALDH1A1
SCHEMBL12163955 0.79 P2RX7 (0.69) P2RX7GRM5POLBSMN1; SMN2LMNA
SCHEMBL9967794 0.78 HPGD (0.62) P2RX7GRM5HTTSMN1; SMN2LMNA
SCHEMBL22811277 0.78 P2RX7 (0.67) P2RX7GRM5POLBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1696915-A1 BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY Pfizer, Inc. (US) 2006-09-06 EP disclosed
US-20050148631-A1 Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AGOURON PHARMACEUTICALS, INC. 2005-07-07 US disclosed
WO-2005060963-A1 BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY PFIZER INC. (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148631-A1 Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B11, HSD11B2 P2RX7 4589/4885GRM5 1735/4885ALOX15 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.